Skip to content

Study · Animal study (in vivo) · horse · 2019

3 results

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

Timms M, Ganio K, Forbes G, Bailey S, Steel R

Drug testing and analysis25 Dec 2018Cited by 4 (Europe PMC)

PMID30489688 (opens in a new tab)DOI10.1002/dta.2554 (opens in a new tab)PepBankPUB-30489688
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    The immuno-PCR assay confirmed CJC‑1295 in equine blood samples after administration to thoroughbred race horses.

    In plain wordsIn horses, the assay found CJC‑1295 in blood samples after the horses received the drug.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    Not applicableDetection in plasma after administration
    Study

    horsen: not reported in source

    Thoroughbred race horses
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effectiveness of the assay for controlling the illicit use of CJC-1295 was confirmed in equine blood samples after administration in thoroughbred race horses.

Studies that did not test the peptide alone2

In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking CJC-1295 (with DAC).

  1. 02LabNot a test of CJC-1295 (with DAC) aloneOther designOther

    An immuno-PCR assay with two monoclonal antibodies detected the CJC‑1295-protein conjugate at concentrations down to 0.8 pg/mL.

    In plain wordsIn lab tests, an antibody-based assay detected CJC‑1295 bound to plasma proteins at very low levels.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    Not applicableI-PCR assay sensitivity for CJC-1295-protein conjugate
    Study

    horsen: not reported in source

    Equine plasma
    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    Detection limit
    0.8 pg/mL
    I-PCR, CJC-1295-protein conjugate

    Source sentences

    Summary
    Using a pair of monoclonal antibodies raised against the CJC-1295 peptide, we present an immuno-polymerase chain reaction (I-PCR) assay that is capable of detecting the CJC-1295-protein conjugate at concentrations down to 0.8 pg/mL.

    In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).

  2. 03LabNot a test of CJC-1295 (with DAC) aloneOther designOther

    Detection of endogenous equine GHRH required a screening threshold for CJC‑1295 in equine plasma of 50 pg/mL.

    In plain wordsIn lab tests, horse plasma needed a screening threshold for CJC‑1295 because the horse makes its own similar hormone.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    Not applicableScreening threshold in equine plasma
    Study

    horsen: not reported in source

    Equine plasma
    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    Screening threshold
    50 pg/mL
    equine plasma

    Source sentences

    Summary
    Detection of endogenous equine GHRH necessitated a screening threshold for CJC-1295 in equine plasma of 50 pg/mL.

    In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.